Anne‐Perrine Foray

Immunological impact of age and comorbidities: findings from the REALISM and SENIOR-HLA-DR cohorts

L. Vieilledent, Sylvain Gaujard, Morgane Gossez, Anne Broyer et autres

BACKGROUND: The ageing population faces numerous physiological changes, among which immunosenescence plays a central role. Understanding the mechanisms underlying immunosenescence remains a priority. Within this framework, the contribution of comorbidities to immune dysfunction is still poorly characterized, despite growing evidence suggesting that …

fr (code pays fourni par la source)

Assessment of soluble PD-L1 in septic shock in relation to immunosuppressive phenotypes

Camille Bonnet, Anne‐Perrine Foray, Eléonore Micoud, Thomas Lafon et autres

Background: Septic shock triggers a complex immune response characterized by the coexistence of hyperinflammation and immunosuppression, the latter being a major driver of ICU-acquired infections and increased mortality. Currently, the most established biomarkers for assessing sepsis-induced immunosuppression rely on flow cytometry-a technique …

fr (code pays fourni par la source)

Dazukibart for the treatment of severe TIF1γ ‐positive juvenile dermatomyositis

Benjamin Fournier, Jamie Sugrue, A. Welfringer‐Morin, Thomas Moreau et autres

The data that support the findings of this study are available from the corresponding author upon reasonable request.

fr (code pays fourni par la source)

Type I interferon as a pre‐lupus marker in anti‐nuclear antibody‐associated childhood immune thrombocytopenic purpura

Jérôme Granel, Helder Fernandes, Élodie Wojciechowski, Pascal Pillet et autres

Paediatric-onset anti-nuclear antibody-associated immune thrombocytopenic purpura (ITP-ANA+) is a pre-lupus condition. Interferon signature (IS) is a reliable method to measure interferon-stimulated gene expression which is commonly raised in systemic lupus erythematosus (SLE) and in adult pre-lupus cases. Between 2022 and 2024, IS …

fr (code pays fourni par la source)

Myositis-specific autoantibody subtypes are associated with response to Janus kinase inhibitors in patients with juvenile dermatomyositis

Brigitte Bader‐Meunier, T. Moreau, Florence A. Aeschlimann, François‐Jérôme Authier et autres

OBJECTIVES: To evaluate the efficacy and safety of Janus kinase inhibitors (JAKi) in a monocentric series of patients with JDM and to identify factors associated with the achievement of clinically inactive disease (CID). METHODS: Single-centre retrospective study of 39 JDM patients treated …

fr, ch (code pays fourni par la source)

Profiling type I and II interferon responses reveals distinct subgroups of pediatric patients with autoinflammatory disorders

Anaïs Nombel, Magali Perret, Sophie Trouillet‐Assant, Marine Villard et autres

Background: Elevation of type I interferon (IFN-I) is characteristic of a group of diseases known as type I interferonopathies. Several technologies are available to monitor IFN-I, but there is no consensus on their routine use in medical laboratories. Objective: We aimed to …

fr, nl (code pays fourni par la source)

Efficacy of BAFF inhibition and B-cell depletion in non-obese diabetic mice as a spontaneous model for Sjögren’s disease

Renaud Felten, Anne‐Perrine Foray, Pascal Schneider, Cindy Marquet et autres

Introduction The therapeutic interest of targeting B-cell activating factor (BAFF) in Sjögren’s disease (SjD) can be suspected from the results of two phase II clinical trials but has not been evaluated in an animal model of the disease. We aimed to evaluate …

fr, ch (code pays fourni par la source)

JAK inhibitors in refractory juvenile rheumatic diseases: Efficacy, tolerance and type-I interferon profiling, a single center retrospective study

Marie Solignac, Natalia Cabrera, Marine Fouillet-Desjonquères, A. Duquesne et autres

OBJECTIVES: - Janus Kinase inhibitors (JAKi) are a new class of drugs available for pediatric rheumatic diseases. This study aimed to describe the safety and effectiveness of JAKi in these diseases, with a focus on longitudinal interferon-stimulated genes (ISG) assessment. METHODS: - …

fr, us (code pays fourni par la source)

Occurrence of Lupus-Like Nephritis in a Girl With NLRC4 Gain-of-Function Mutations

Franck Zekre, Audrey Laurent, Bruno Ranchin, Anne‐Perrine Foray et autres

NLRC4 belongs to the family of innate immunity receptors. These receptors have the ability to detect microbial patterns and molecular signals of cellular damage within the cell. The involvement of NLRC4 in autoinflammatory pathologies was highlighted in 2014, when infantile enterocolitis and …

fr (code pays fourni par la source)

Assessment of type I interferon response in routine practice in France in 2022

Anaïs Nombel, Anne‐Perrine Foray, Lorna Garnier, Christine Lombard et autres

An European Alliance of Associations for Rheumatology task force recently recommended specific points to consider for exploring type I interferon pathway in patients, highlighting the lack of analytical assays validated for clinical routine. We report here the French experience on a type …

fr (code pays fourni par la source)

Exploration immunologique de l’œil

Rémi Pescarmona, Anne‐Perrine Foray, Lorna Garnier

fr (code pays fourni par la source)

De novo germline mutation in the dual specificity phosphatase 10 gene accelerates autoimmune diabetes

Anne‐Perrine Foray, Sophie Candon, Sara Hildebrand, Cindy Marquet et autres

Significance The vast majority of autoimmune diseases are polygenic, and causal loci uncovered by genetic-mapping studies explain only a minority of the heritable contribution to trait variation. Multiple explanations for this missing heritability include rare meaningful variants, rare copy number variations or …

fr, us, es, ca, gb (code pays fourni par la source)